J&J's Janssen: FDA OK's Xarelto in Acutely Ill Medical Patients
14 Oktober 2019 - 3:52PM
Dow Jones News
By Colin Kellaher
Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. unit
Monday said the U.S. Food and Drug Administration approved the
blood thinner Xarelto for the prevention of venous thromboembolism,
or blood clots, in acutely ill medical patients.
Janssen said the approval for Xarelto, which it jointly
developed with Germany's Bayer AG (BAYN.XE), covers hospitalized
acutely ill medical patients at risk for thromboembolic
complications who aren't at high risk of bleeding.
Janssen said the FDA has granted Xarelto eight indications,
including six specifically for the treatment, prevention and
reduction in the risk of recurrence of venous thromboembolism
across a range of patient populations.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 14, 2019 09:37 ET (13:37 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Bayer (TG:BAYN)
Historical Stock Chart
Von Mär 2024 bis Apr 2024
Bayer (TG:BAYN)
Historical Stock Chart
Von Apr 2023 bis Apr 2024